Alkermes (NasdaqGS:ALKS) has drawn fresh attention after presenting new clinical and real world data on LYBALVI and ARISTADA at major psychiatry and health economics conferences, highlighting outcomes in schizophrenia, bipolar I disorder, and sleep medicine.

These research updates land at a time when Alkermes’ share price has moved to US$39.94, with a 30 day share price return of 16.99% and a year to date share price return of 41.33%. The 1 year total shareholder return of 32.03% points to momentum that has been building over both shorter and longer periods.

If this kind of neuroscience and mental health focus interests you, it can be useful to widen the search and see what other healthcare related AI opportunities are doing through the 35 healthcare AI stocks

With Alkermes trading at US$39.94, a 30 day return of 16.99% and an indicated discount to both analyst targets and intrinsic value, the key question is whether there is still an opportunity for investors or if markets are already pricing in future growth.

Most Popular Narrative: 9.7% Undervalued

Alkermes’ most followed narrative places fair value at $44.24 against the last close of $39.94, framing the recent share price strength as still leaving room to the modeled intrinsic value, using a 7.6% discount rate.

Results from the Vibrance 1 Phase II study and the expanding orexin agonist pipeline de risk the company's long term R&D strategy, opening avenues to additional addressable disorders beyond narcolepsy and highlighting potential for future multi indication revenue streams pending successful late stage trials and commercialization.

Want to understand why this story supports a higher fair value than the current price? The narrative leans on stronger modeled revenue growth, shifting margins and a richer earnings multiple than today. The key is how those pieces fit together over several years, not just the next quarter.

Result: Fair Value of $44.24 (UNDERVALUED)

However, the story can change quickly if orexin trials disappoint or if heavier R&D spending and reliance on a few key products begin to pressure margins.

Another View: What The Market Multiple Is Signalling

While the SWS DCF model suggests Alkermes is trading 56.9% below an estimated fair value of $92.67, the share price tells a different story when you look at P/E. At 43.6x, the stock trades well above the US Biotechs average of 16.3x, the peer average of 29.2x, and a fair ratio of 29.7x, which points to valuation risk if expectations slip. How comfortable are you paying that kind of premium?

Next Steps

After weighing both the upbeat and cautious parts of this story, are you ready to look at the data yourself and move quickly to shape your own view by weighing up the 2 key rewards and 2 important warning signs?

Looking for more investment ideas?

If Alkermes has your attention, do not stop here. Use the screener to spot other stocks that match your style before the next move passes you by.

• Target dependable cash generators by scanning for companies with strong balance sheets and fundamentals through the solid balance sheet and fundamentals stocks screener (46 results).
• Spot potential value opportunities early by checking out the 46 high quality undervalued stocks that combine quality fundamentals with prices below modeled fair value.
• Add extra resilience to your watchlist by reviewing the 64 resilient stocks with low risk scores that score well on financial health and risk indicators.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.